State-of-the-Art Clinical Symposium

Updated faculty information coming soon

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience any financial or other relationship(s) including, but not limited to:

1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
2. Research grants
3. Employment (full or part-time)
4. Ownership or partnership
5. Consulting fees or other remuneration (payment)
6. Non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson
7. Receipt of royalties
8. Speakers' bureau
9. Other

The planning committee and faculty reported the following disclosures.

State-of-the-Art Clinical Symposium Planning Committee

• Meenakshi Jolly, MD, MS - Rush University⁷, Pfizer²
• Narender Annapureddy, MD, MS - No relevant financial relationships to disclose
• Francesco Boin, MD - No relevant financial relationships to disclose
• Liana Fraenkel, MD, MPH - No relevant financial relationships to disclose
• Lianne Gensler, MD – Novartis², Pfizer², UCB², Abbvie⁵, Galapagos⁵, Janssen⁵
• Manjari Malkani, MD - No relevant financial relationships to disclose
• Rebecca Manno, MD - Sanofi⁵, Novartis², Paradigm Education⁵
• Michael Putman, MD - No relevant financial relationships to disclose

State-of-the-Art Clinical Symposium Faculty

• Francesco Boin, MD - No relevant financial relationships to disclose
• Eliza F. Chakravarty, MD - No relevant financial relationships to disclose
• Erika Darrah, PhD - No relevant financial relationships to disclose
• Kevin Deane, MD, PhD - BMS⁵, Inova Diagnostics Inc.^{5, 2}, Janssen², Microdrop, Inc.⁵, ThermoFisher Scientific ⁵
• Tracy Frech, MD - No relevant financial relationships to disclose
• Marvin Fritzler, MD, PhD - Aesku⁵, Alexion Canada: Diagnostic test support^{2, 9, 8}, Euroimmun GmbH⁹, Inova Diagnostics Inc. ^{5, 8}, Werfen Inernational^{5, 8}
• Jon Giles, MD, MPH - AbbVie 5; Bristol Myers Squibb Co., Ltd. 5; Eli Lilly and Co. ⁵, Pfizer², Roche/Genentech⁵, UCB Pharma⁵
• Nigil Haroon, MD, PhD, DM, FRCPC - AbbVie⁵, Amgen⁸, Eli Lilly⁸, Janssen⁵, Novartis⁵, Novo Nordisk⁸, UCB⁵
• Laura Hummers, MD - Boehringer Ingelheim^{5, 2}, Corbus Pharmaceuticals² CSL Behring^{5, 2} Cumberland², EICOS², Glaxo Smith Kline², Kadmon²
• Tanaz Kermani, MD - Genentech^{5, 9}
• Walter Maksymowych, MD, FRCPC - AbbVie, Boehringer Ingelheim, CARE Arthritis, Celgene, Ely Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, CARE Arthritis ^{5, 2, 9, 8}
• Joan Merrill, MD - Abbvie^{5, 8}, Amgen⁵, Astellas⁵, Astra Zeneca⁵, Bristol Myers Squibb Co. Ltd. ^{5, 2}, Celgene⁵, Daiichi Sankyo⁵, EMD Serono⁵, Glaxo Smith Kline^{5, 2}, ILTOO⁵, Immupharma⁵, Incyte⁵, Janssen⁵, Lilly⁵, Remegen⁵, Servier⁵, Zencor²
• Tuhina Neogi, MD, PhD, FRCPC - EMD Merck Serono⁵, Novartis⁵, Pfizer⁵
• James T. Rosenbaum, MD - AbbVie⁵
• Deborah Sellmeyer, MD - No relevant financial relationships to disclose
• Ami Shah, MD - No relevant financial relationships to disclose